Talk Bio

A bipartisan U.S. Senate bill unveiled in July 2026 seeks to increase scrutiny of foreign companies making drugs in the United States, driven by concerns about national security and public health risks from overreliance on foreign manufacturing and investment. The Pharmaceutical Investment Oversight and Accountability Act, introduced by Senators Elizabeth Warren (D‑Mass.), Rick Scott (R‑Fla.), and Kirsten Gillibrand (D‑N.Y.), would require the Federal Trade Commission (FTC) and the Department of Treasury—with input from CFIUS—to produce an annual report to Congress examining foreign investment in the U.S. pharmaceutical industry. The bill would require regulators to assess how foreign manufacturing and capital affect the U.S. drug supply, including shifts of domestic plants overseas, and the impact of foreign stakes in DNA sequencing and biotech infrastructure, with the goal of improving transparency and vigilance around foreign‑owned drugmakers operating in the U.S. Sources: W...